[Skip to Content]
[Skip to Content Landing]
Views 2,274
Citations 0
News From the Food and Drug Administration
July 16, 2019

Chemoimmunotherapy for Lymphoma

JAMA. 2019;322(3):199. doi:10.1001/jama.2019.9918

A novel antibody-drug conjugate (ADC) for adults with refractory or relapsing diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, has received accelerated FDA approval. Up to 40% of patients with DLBCL will relapse.

Polatuzumab vedotin is indicated for patients whose DLBCL has progressed or returned after at least 2 previous therapies. It is intended for use in combination with the standard chemotherapy regimen bendamustine plus rituximab (BR).